2022

1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

   The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45